Officer Daniel Long proposes selling 10,001 Septerna (SEPN) common shares.
Septerna officer Daniel Long has proposed selling 10,001 common shares of SEPN, valued at approximately $391,339.13, with an approximate sale date of October 1, 2026. These shares are to be acquired through stock option exercises over the next three months. The filing also notes two prior 10b5-1 sales by Long: 3,333 shares on September 1, 2026, and 3,334 shares on August 3, 2026.
Septerna Officer Samira Shaikhly Files Form 144 to Sell 12,592 Common Shares
Septerna officer Samira Shaikhly has filed a Form 144 to sell 12,592 shares of the company's common stock, valued at over $492,000. These shares were acquired through the exercise of stock options on October 1, 2026, and the sale will be conducted on NASDAQ via Morgan Stanley Smith Barney LLC under a Rule 10b5-1 trading plan. This disclosure indicates no prior sales by Shaikhly in the preceding three months and confirms she is unaware of any undisclosed material adverse information about Septerna.
An officer proposes selling 12,592 Septerna (SEPN) shares acquired by exercising stock options.
Septerna, Inc. officer Samira Shaikhly has proposed selling 12,592 common shares with an aggregate market value of $492,724.96. These shares were acquired on October 1, 2026, through the exercise of stock options for cash. The proposed sale is being handled by Morgan Stanley Smith Barney LLC and the approximate sale date is October 1, 2026.
SEPN - Long-Term GPCR Platform And Novo Nordisk Collaboration Will Drive Future Value Potential
Septerna (SEPN) is seen as undervalued by analysts, who predict significant future value driven by its GPCR platform, lead drug candidates SEP-479 and SEP-631, and a collaboration with Novo Nordisk. Key catalysts include positive Phase 1 data for SEP-479 in hypoparathyroidism and advancements in other pipeline programs. Despite an expected near-term revenue decrease, analysts project long-term profit margin growth and a consensus price target of $54.22, implying a substantial upside from the current share price.
Septerna, Inc. - Common Stock (NQ: SEPN)
This article provides recent news headlines for Septerna, Inc. (Nasdaq: SEPN), including analyst coverage initiations with "Overweight" ratings and price targets of $50 and $38 due to the company's innovative GPCR platform and pipeline. It also lists other premarket stock movements and IPO-related news for different companies.
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
Septerna (SEPN) is attending upcoming healthcare conferences, generating investor interest despite recent share price fluctuations. While the company shows strong long-term momentum, its current Price-to-Sales (P/S) ratio of 18.2x is significantly higher than industry averages and its estimated fair value, suggesting it may be overvalued based on future pipeline potential rather than current financials. Investors are advised to critically assess the company's valuation, considering both potential upsides and risks like clinical data disappointments or revenue declines.
Septerna (SEPN) awards CMO 275,000 options at $37.37
Septerna, Inc. (SEPN) announced that its Chief Medical Officer, Rajiv Patni, was granted 275,000 stock options on September 8, 2026, with an exercise price of $37.37 per share and an expiration date of September 7, 2036. The options will vest over time, with 25% vesting on August 24, 2027, and the remaining 75% in monthly installments, contingent on his continuous service. This grant resulted in Patni holding 275,000 options for the company.
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna, Inc. announced an inducement grant of a non-qualified stock option to purchase up to 275,000 shares of its common stock to its new Chief Medical Officer, Rajiv Patni, M.D. This grant, effective September 8, 2026, was made under the Company's 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $37.37 per share and vests over four years, subject to continuous employment.
Septerna's CMO Rajiv Patni Granted 275,000 Stock Options with 10-Year Expiry
Septerna, Inc.'s Chief Medical Officer, Rajiv Patni, was granted stock options for 275,000 common shares on September 8, 2026. The options have an exercise price of $37.37 per share and will expire on September 7, 2036. The vesting schedule requires continuous service, with 25% vesting in August 2027 and the remaining 75% vesting monthly over 36 months.
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna, Inc. announced an inducement grant of a non-qualified stock option to purchase up to 275,000 shares of its common stock to Rajiv Patni, M.D., the new Chief Medical Officer. The grant, effective September 8, 2026, has an exercise price of $37.37 per share and vests over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). Septerna is a clinical-stage biotechnology company focused on GPCR therapies.
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna, Inc. announced a non-qualified stock option grant to Rajiv Patni, M.D., the new Chief Medical Officer, for up to 275,000 shares of common stock. The grant, effective September 8, 2026, was an inducement for his employment and vests over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4).
Septerna SVP Daniel Long sells $126,077 in company stock By Investing.com
Septerna's SVP of Drug Discovery, Daniel D. Long, sold $126,077 worth of company stock and exercised options valued at $9,199 on September 1, 2026. The sale of 3,333 shares at a weighted average price of $37.8271 was executed under a Rule 10b5-1 sales plan. Following these transactions, Long directly holds 96,412 shares and beneficially owns 9,085 exercisable stock options.
Septerna SVP Daniel Long sells $126,077 in company stock
Septerna's SVP of Drug Discovery, Daniel Long, recently sold 3,333 shares of company stock for $126,077 while simultaneously acquiring the same number of shares through stock option exercises for $9,199. These transactions were part of a Rule 10b5-1 sales plan. Analysts maintain a "strong buy" rating for Septerna, with price targets ranging from $48 to $62, reflecting positive developments in its drug pipeline despite some competitive setbacks.
New Septerna (SEPN) chief medical officer reports zero share holdings
Septerna's new Chief Medical Officer, Rajiv Patni, has filed an initial ownership report (Form 3) indicating that he currently holds no shares or equity in the company. This filing, which is a standard procedure for new officers, also includes an Exhibit 24 Power of Attorney. The report clarifies that there are no reported purchases, sales, or other equity transactions by Patni as of the filing date.
Septerna to Participate in Upcoming Investor Conferences
Septerna, Inc., a clinical-stage biotechnology company focused on GPCR drug discovery, announced its participation in two investor conferences in September 2026. Management will hold fireside chats at the Wells Fargo 21st Annual Healthcare Conference on September 8th and the Cantor Global Healthcare Conference 2026 on September 10th. Webcasts of these presentations will be available on the company's website.
Septerna Inc Q2 Income From Operations USD -1
This article states that Septerna Inc. reported an income from operations of USD -1 for the second quarter.
Is Septerna (SEPN) Elevating Its Clinical Strategy With a Veteran Regulatory Leader at the Helm?
Septerna, Inc. recently appointed Rajiv Patni, M.D., as Chief Medical Officer, bringing over 25 years of biopharmaceutical leadership experience in research, development, regulatory, and medical affairs. His track record of securing 10 regulatory approvals and leading companies later acquired could bolster investor confidence in Septerna's pipeline and clinical execution. While the appointment is seen as incrementally positive for advancing clinical milestones, the company remains unprofitable with a high price-to-sales multiple, and its current valuation might already reflect significant optimism.
Septerna appoints Rajiv Patni as chief medical officer By Investing.com
Septerna, Inc. has announced the appointment of Rajiv Patni, M.D., as its new Chief Medical Officer. Dr. Patni brings over 25 years of biopharmaceutical experience, having previously held significant roles at companies like Judo Bio and Reata Pharmaceuticals. His expertise spans research, development, regulatory affairs, and medical operations, with a track record of contributing to 10 regulatory approvals.
Septerna appoints Rajiv Patni as chief medical officer
Septerna, Inc. has announced the appointment of Rajiv Patni, M.D., as its new Chief Medical Officer. Dr. Patni brings over 25 years of experience in biopharmaceutical research and development, with a successful track record in guiding investigational medicines through regulatory approvals. He will oversee Septerna's clinical development programs for its G protein-coupled receptor drug candidates.
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Septerna, Inc., a clinical-stage biotechnology company, has announced the appointment of Rajiv Patni, M.D., as its new Chief Medical Officer. Dr. Patni brings over 25 years of experience in biopharmaceutical research and development, with a successful track record in guiding investigational medicines through regulatory approvals. His appointment is expected to be instrumental in advancing Septerna's clinical programs and pipeline targeting unmet medical needs in various therapeutic areas.
Septerna Appoints Rajiv Patni as Chief Medical Officer
Septerna, a clinical-stage biotech company, has appointed Rajiv Patni, M.D., as its new Chief Medical Officer, effective August 25, 2026. Dr. Patni brings over 25 years of experience in biopharmaceutical research, development, regulatory, and medical affairs, having contributed to 10 regulatory approvals or label expansions. His appointment is expected to bolster Septerna's efforts to advance its pipeline of GPCR-targeted oral medicines for various therapeutic areas.
Septerna (NASDAQ:SEPN) Stock Price Down 8% - Time to Sell?
Septerna's stock (NASDAQ:SEPN) recently dropped 8% to $40.41, with trading volume significantly below its average. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $52.44, citing the company's beat on quarterly earnings expectations. However, insider selling of 72,828 shares worth approximately $2.68 million over the last quarter raises questions for potential investors.
J.P. Morgan Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $48
J.P. Morgan analyst Tessa Romero has reiterated a Buy rating on Septerna (SEPN.US) and increased the target price from $38 to $48. Romero has a 57.6% success rate and an average return of 20.7% over the past year, according to TipRanks data. This adjustment reflects continued confidence in Septerna's stock performance.
SEPTERNA, INC. : JP MORGAN RAISES TARGET PRICE TO $48 FROM $38
J.P. Morgan has raised its target price for SEPTERNA, INC. (SEPN.O) to $48 from the previous $38. This update reflects the analyst's revised outlook on the company's valuation. The article states that this content solely reflects the author's opinion and is not investment advice.
4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC
Trv Gp Vi LLC has acquired over 4.2 million shares of Septerna, Inc. (NASDAQ:SEPN) valued at approximately $141 million, making it their largest portfolio holding with a 9.34% stake. This acquisition comes amidst positive analyst sentiment, with an average "Moderate Buy" rating and a price target of $51.33, and Septerna beating quarterly earnings expectations. However, some insiders have recently sold shares, though the company itself is a clinical-stage biotechnology firm focused on GPCR oral small molecule drug discovery.
Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN
Trv Gp V LLC has acquired a significant new position in Septerna, Inc. (NASDAQ:SEPN) during the second quarter, making it their second-largest holding. Other institutional investors like BlackRock and Goldman Sachs have also increased their stakes, indicating growing institutional interest. Despite some insider selling, analysts maintain a "Moderate Buy" consensus for Septerna, which also exceeded revenue and EPS expectations in its latest quarterly report.
Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst
Stifel Nicolaus analyst Alex Thompson CFA reiterated a Buy rating on Septerna, Inc. (SEPN) and set a $46.00 price target. This comes as corporate insider sentiment for SEPN is negative, with an increase in insider selling. The company recently reported Q2 revenue of $26.75 million and a GAAP net loss of $13.03 million.
Septerna Inc stock hits all-time high at 50.0 USD
Septerna Inc's stock recently achieved an all-time high of $50, reflecting a 326% increase over the past year and a 71% year-to-date return, driven by strong investor confidence. The company's market capitalization stands at $2.28 billion, with the stock currently trading at $49.47. Analyst price targets for Septerna's drug candidate SEP-479 vary, with H.C. Wainwright maintaining a Buy rating despite a competitor's setback.
37,700 Shares in Septerna, Inc. $SEPN Purchased by Renaissance Technologies LLC
Renaissance Technologies LLC has acquired a new stake of 37,700 shares in Septerna, Inc. (NASDAQ:SEPN) valued at $906,000. This comes as Septerna reported better-than-expected quarterly results and received positive sentiment from analysts, with a consensus "Moderate Buy" rating and an average price target of $51.33. Despite positive analyst outlooks and strong earnings, insiders have sold a significant number of shares recently.
Ra Capital Management sells $63.45m in Septerna stock
RA Capital Management, a major shareholder in Septerna Inc. (NASDAQ:SEPN), sold 1,493,000 shares of common stock for a total of $63.45 million on August 12, 2026. The sale occurred after Septerna's stock surged 280% over the past year, with shares trading at $42.50 during the transaction. Despite the sale, RA Capital Healthcare Fund and RA Capital Nexus Fund III still hold significant indirect stakes in Septerna.
Driehaus Capital Management (SEPN) discloses 4.43M-share Septerna stake in 13G/A
Driehaus Capital Management LLC has filed an amended Schedule 13G/A, reporting a beneficial ownership of 4,433,058 shares of Septerna, Inc. common stock, which represents 9.83% of the class. Driehaus holds shared voting and dispositive power over these shares, managed across numerous client accounts. The filing clarifies that no single underlying client is known to have rights to dividends or sale proceeds for more than 5% of Septerna's common stock.
Third Rock Ventures V, L.P. director sells $7.4m Septerna shares
Third Rock Ventures V, L.P., a significant shareholder and director of Septerna, Inc., sold 147,200 shares of the company's common stock for approximately $7.4 million on August 12, 2026. The sales were executed through a pre-arranged trading plan, with shares trading near their 52-week high, reflecting a 281% return over the past year. Following these transactions, Third Rock Ventures V, L.P. still directly holds over 6 million shares, while another entity, Third Rock Ventures VI, L.P., holds over 4 million shares indirectly.
Form 4: Third Rock Ventures reports acquisition/exercise transactions in SEPN
Third Rock Ventures V, L.P. reported insider transactions in Septerna, Inc. (SEPN) through a Form 4 filing, indicating sales of 147,200 shares at a weighted average price of $50.27 per share. These transactions, executed on August 12, 2026, were conducted under a Rule 10b5-1 trading plan. After these sales, Third Rock Ventures entities still hold a substantial number of SEPN shares, with Third Rock Ventures V, L.P. directly holding 6,068,391 shares and Third Rock Ventures VI, L.P. indirectly holding 4,211,659 shares.
Septerna (SEPN): RA Capital funds disclose sale of 1.49M common shares
RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P. reported the sale of 1,493,000 common shares of Septerna, Inc. (SEPN) on August 12, 2026, at a price of $42.50 per share. The sales were made by affiliated entities of RA Capital, with Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their pecuniary interests. Following these transactions, RA Capital's indirect holdings in Septerna stand at 725,443 shares.
RA Capital group (SEPN) discloses 11.8% Septerna stake and major block sales
RA Capital Management and its associated entities have disclosed a beneficial ownership of 11.8% in Septerna, Inc. (SEPN), totaling 5,525,324 shares. This updated filing, a Schedule 13D/A, details holdings across various funds and includes significant block sales made on August 12, 2026, where RA Capital Healthcare Fund and RA Capital Nexus Fund III each sold 746,500 shares at $42.50 per share. The report also outlines vested stock options held for RA Capital's benefit with specified exercise prices.
Price to sales forward of Septerna, Inc. – NASDAQ:SEPN
This article provides information about the "Price to sales forward" metric for Septerna, Inc. (NASDAQ: SEPN) as listed on TradingView. It indicates that the market was closed at the time of viewing, with no trades for the company. The content primarily consists of navigation links and disclaimers related to the TradingView platform.
Septerna (SEPN) President & COO exercises 25,000 options and sells shares under 10b5-1 plan
Septerna, Inc. President and COO Elizabeth Bhatt exercised 25,000 stock options on August 11, 2026, with exercise prices of $6.81 for 18,681 shares and $2.76 for 6,319 shares. On the same day, she sold all 25,000 Common Stock shares at $44.00 per share. This sale was conducted under a pre-arranged Rule 10b5-1 sales plan adopted on October 20, 2025.
Septerna president & COO Elizabeth Bhatt disposes of $1.1m in stock
Elizabeth Bhatt, President and COO of Septerna, Inc. (NASDAQ:SEPN), sold 25,000 shares of common stock for $1.1 million on August 11, 2026, after acquiring them through stock option exercises. These transactions were executed under a Rule 10b5-1 sales plan, leaving Bhatt with 174,209 directly owned shares and 144,562 stock options. The company's stock has seen significant returns, and analysts have recently issued mixed but generally optimistic updates on Septerna's drug pipeline.
Septerna, Inc. SEC Filing (Aug 12, 2026)
Septerna, Inc. has filed a Form 144 with the SEC on August 12, 2026, indicating a proposed sale of securities. The filing details the sale of 746,500 common shares acquired through an IPO on October 25, 2024, with an aggregate market value of $35,973,835.00, to be handled by BTIG LLC.
SEPN (SEPN) plans NASDAQ sale of 746,500 shares worth $35.97M
Septerna, Inc. (SEPN) has filed a Form 144 indicating its intent to sell 746,500 common shares on NASDAQ through broker BTIG LLC, with an aggregate market value of $35,973,835.00. These shares were acquired in two blocks in May and October 2024 through IPO settlement or private funding. The company currently has 46,676,947 common shares outstanding.
Does Septerna (SEPN) Pair Narrowing Losses With A Cash Runway That Truly Supports Its Pipeline Strategy?
Septerna, Inc. reported narrowing net losses and increased sales in Q2 2026, driven by a collaboration with Novo Nordisk. The company reiterated its cash runway into 2029, supporting its early-stage clinical pipeline. Despite positive financial updates, the article notes ongoing concerns regarding Septerna's valuation and potential risks from clinical data or partner momentum.
Septerna Inc stock hits all-time high at 50.0 USD By Investing.com
Septerna Inc (SEPN) stock has reached an all-time high of $50, currently trading at $49.47 with a market capitalization of $2.28 billion, reflecting a 326% increase over the past year. InvestingPro analysis suggests the stock is fairly valued, with significant momentum highlighted by a 71% year-to-date return. This comes amidst recent analyst updates on its drug candidate SEP-479, with H.C. Wainwright, Stifel, and Guggenheim adjusting price targets based on trial progress and competitive landscape.
H.C. Wainwright raises Septerna stock price target to $60 on SEP-479 progress
H.C. Wainwright increased its price target for Septerna Inc (NASDAQ:SEPN) to $60 from $40, maintaining a Buy rating, due to positive progress in the Phase 1 trial of SEP-479 for hypoparathyroidism. The drug shows a favorable pharmacokinetic profile supporting once-daily dosing, with full Phase 1 data expected in Q1 2027. This update aligns with other analysts like Stifel, Guggenheim, and Truist, who have also raised their price targets for Septerna based on the promising SEP-479 pipeline.
Septerna, Inc. Stock 12‑Month Price Target Raised to $47, Implies 21% Upside
Septerna, Inc.'s average 12-month price target has been increased from $45 to $47 by 9 analysts, with individual forecasts ranging from $38 to $60 per share. This new target suggests a potential upside of approximately 21% based on the August 10 closing price. The consensus rating for SEPN remains a "Buy" across 10 covering analysts.
Seer (SEPN) insiders plan sale of 29,000 shares after option exercise
Seer, Inc. (SEPN) has filed a Form 144 notice to allow the potential sale of 29,000 common shares by an affiliate, following an option exercise on August 11, 2026, valued at $1,126,650.00. The filing also disclosed a previous sale of 4,000 shares on July 15, 2026, under a Rule 10b5-1 plan for Elizabeth P. Bhatt, generating $135,974.00. Morgan Stanley Smith Barney LLC will handle the planned share sale.
Septerna, Inc. Stock 12‑Month Price Target Raised to $46.78, Implies 20% Upside
Analysts have raised Septerna, Inc.'s average 12-month price target from $45 to $47, with forecasts ranging from $38 to $60 per share. This new target implies a potential upside of approximately 21% from the August 10th closing price. The consensus rating from 10 analysts remains a "Buy," with no "Holds" or "Sells."
Raymond James Maintains Septerna(SEPN.US) With Buy Rating, Cuts Target Price to $49
Raymond James has reiterated its Buy rating for Septerna (SEPN.US) but has adjusted its price target downwards to $49. This indicates a continued positive outlook on the company's prospects despite a revision in the expected share price. Investors may see this as a signal that the firm believes Septerna still has significant upside potential.
Septerna (NASDAQ:SEPN) Stock Price Up 9% Following Earnings Beat
Septerna (NASDAQ:SEPN) shares rose 9% after reporting better-than-expected quarterly earnings, with an EPS of negative $0.29 against estimates of negative $0.43, and revenue of $26.75 million exceeding the $19.22 million consensus. Despite broad analyst positivity and a "Moderate Buy" consensus rating, the company remains unprofitable with negative net margins. Insider selling of 47,828 shares worth approximately $1.58 million has been noted in the last 90 days, even as institutional investors increased their positions.
Stifel raises Septerna stock price target to $49 on SEP-479 outlook
Stifel increased its price target for Septerna Inc (NASDAQ:SEPN) shares to $49 from $43, maintaining a Buy rating. This adjustment is based on an increased probability of success for their drug candidate SEP-479, a first-in-class oral PTH1R agonist for hypoparathyroidism. The company has also re-evaluated its development plans for SEP-631 following a competitor's setback.
Stifel raises Septerna stock price target to $49 on SEP-479 outlook
Stifel has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $49 from $43, maintaining a Buy rating due to an improved outlook for SEP-479, a hypoparathyroidism drug. The firm raised the drug's probability of success to 50% from 33% based on positive preclinical data and strong market reception for similar treatments. Despite some developmental uncertainties with another drug, SEP-631, Septerna maintains a strong financial position, and other analysts like Guggenheim, H.C. Wainwright, Truist Securities, and Raymond James also hold positive outlooks on the company.
